Japanese Biotech Craif Expands its Innovative Diagnostic Platform to the U.S. Market

Japanese biotechnology company Craif has completed a $33 million Series D funding round, marking a significant step in its expansion into the U.S. liquid biopsy market. The round was co-led by Granite-Integral, an Asian venture capital firm, and Tauns Laboratories, a Japanese manufacturer specializing in diagnostic devices. Craif's miSignal, a urine-based cancer diagnostic platform developed in-house, utilizes artificial intelligence (AI) to analyze cancer-specific microRNA profiles present in urine, maximizing early detection rates. This innovative medical device software (SaMD) has already achieved commercial success in Japan, with over 2,500 medical institutions and 4,500 pharmacies adopting the platform, resulting in over 110,000 prescriptions. The substantial investment will be entirely allocated to conducting new, prospective clinical studies in the U.S., a market with high demand for early diagnosis but facing challenges in securing insurance coverage.

Transforming Early Detection of Pancreatic Cancer, One of the Most Deadly Cancers

Craif's miSignal is initially targeting pancreatic cancer, one of the deadliest forms of cancer, as its primary indication. According to the American Cancer Society (ACS), approximately 67,530 new cases of pancreatic cancer are expected in the U.S. annually, with a dismal 5-year survival rate of only 13%, highlighting the urgent need for early detection screening. Currently, the standard of care for pancreatic cancer diagnosis relies on expensive imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI), as well as invasive tissue biopsies or less accurate blood-based biomarkers like CA19-9. The miSignal technology, which detects subtle molecular signals of pancreatic cancer from a single urine sample, promises to significantly improve upon the high cost and physical discomfort associated with existing diagnostic methods, ushering in an era of patient-friendly, non-invasive screening. The global market for pancreatic cancer diagnostics is projected to reach $3.97 billion by 2026, indicating substantial commercial potential.

Establishing a U.S. R&D Hub in San Diego and Building a Top-Tier Clinical Strategy

In conjunction with the investment, Craif has appointed Dr. Nick Bevins, a physician-scientist, as Chief Medical Officer (CMO) to lead the prospective clinical trials. Dr. Bevins will play a crucial role in designing U.S. clinical trials, securing regulatory approvals from the Food and Drug Administration (FDA), and obtaining reimbursement coverage from U.S. health insurance providers. Craif established a U.S. subsidiary four years ago and, in April of this year, opened a dedicated bio-AI research center in San Diego, a major biotech hub, demonstrating its commitment to localizing its operations in the U.S. market. Ryuichi Onose, CEO and founder, has relocated to San Diego to directly oversee the U.S. expansion, underscoring the company's dedication to focusing its resources on U.S. clinical trials. This strategic move reflects a venture capital-style growth strategy aimed at not only expanding internationally but also securing broad adoption through successful navigation of the stringent U.S. health insurance listing process.

Maximizing Market Dominance in Japan Through Strategic Business Partnerships

To strengthen its presence in the domestic market, Japan, alongside its U.S. expansion, Craif has entered into a strategic business alliance with Tauns Laboratories. Through this partnership, Tauns will gain exclusive sales rights for miSignal in Japan and for the pancreatic cancer diagnostic SaMD software currently under development. Tauns' expertise in developing rapid diagnostic kits and its extensive distribution network will complement Craif's diagnostic software technology, accelerating commercial sales. Tauns' participation as a co-lead investor in the Series D funding round, securing an equity stake, further solidifies the alliance between the two companies. This arrangement enables Craif to leverage stable licensing revenue from the Japanese market to reinvest in the costly U.S. clinical trials and global expansion, creating a virtuous cycle.